AlloLife - Life After Transplantation
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital, Essen
About this trial
Survivors of allo HCT can experience long-term survival, which is however limited by a number of late effects. These will be addressed in AlloLife to improve quality of life (QoL) and survival.
Eligibility criteria
Qualifiers
Age > 18
Patients with performed allogeneic stem cell transplantation any type of donor, stem cell source, GVHD prophylaxis or conditioning regimen and at least at day +20 after HCT.
Hematologic Remission after HCT at study entrance, MRD positive patients are allowed to enter the study
Eastern Cooperative Oncology Group (ECOG) performance status of 0-3
Disqualifiers
Missing consent to use a wearable device and contribute personal data collected at the point of life to the study
ECOG performance status of 4
Relapse of the disease at study inclusion
Uncontrolled systemic infection
Trial design
Treatments tested in this trial
- Technology supported, coordinated survivorship care using wearable devices, supportive patient-apps and cardio-oncology physician apps
Treatment groups
192 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
University Hospital, Essen
Lead sponsor
Universität des Saarlandes
Collaborator
Institut Paoli-Calmettes
Collaborator
Medical University of Warsaw
Collaborator
University Of Perugia
Collaborator
Centre for Research and Technology Hellas
Collaborator
Source ClinicalTrials.gov